Cantourage Group SE Reports Strong Revenue Growth for 2025

Cantourage Group SE has released its preliminary figures for 2025, showing substantial growth. The company's revenue surged to EUR 92.8 million, marking an 82.3% increase from the previous year. The preliminary EBITDA also rose to EUR 5.7 million, up from EUR 3.8 million.

International expansion has played a critical role in this growth, particularly in the UK, which now accounts for over 20% of the total revenue. Cantourage's strategic positioning as a pan-European pharmaceutical company is further stabilizing its operations through economies of scale and optimized supply chains.

Despite facing increased price competition in Germany's low-price cannabis segment, Cantourage is adjusting by focusing on high-margin premium products. This strategic shift aims to enhance profitability in the German market while leveraging long-term supply partnerships.